Expert Opinion on Drug Safety, Volume 22, Issue 4 (2023)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Drug Safety, Volume 22, Issue 4 (2023)

See all volumes and issues
Vol 23, 2024 Volume 22, 2023 Vol 21, 2022 Vol 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Editorial

Editorial
There is no single gold standard study design (RCTs are not the gold standard)
B. Burt Gerstman
Pages: 267-270
Published online: 19 Apr 2023
First Page PreviewforThere is no single gold standard study design (RCTs are not the gold standard) | Full Text | References | PDF (200.7 KB) | EPUB
  • 1799 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Safety Evaluation

Article
Benefit and risk evaluation of quinapril hydrochloride
Maryam Barkhordarian, Jannel A. Lawrence, Sebahat Ulusan, Muhammed Ibrahim Erbay, Wilbert S. Aronow & Rahul Gupta
Pages: 271-277
Published online: 17 Apr 2023
AbstractforBenefit and risk evaluation of quinapril hydrochloride | Full Text | References | PDF (827.9 KB) | EPUB
  • 164 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
Matteo Rosellini, Elisa Tassinari, Andrea Marchetti, Valentina Tateo, Giacomo Nuvola, Alessandro Rizzo, Francesco Massari & Veronica Mollica
Pages: 279-291
Published online: 16 Apr 2023
AbstractforAn update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma | Full Text | References | PDF (1.4 MB) | EPUB
  • 458 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
The safety of phthalate-containing medications used during pregnancy
Amaan Ali, Jan Stener Jørgensen & Ronald F Lamont
Pages: 293-302
Published online: 05 May 2023
AbstractforThe safety of phthalate-containing medications used during pregnancy | Full Text | References | PDF (323.6 KB) | EPUB
  • 152 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
TBC and COVID: an interplay between two infections
Giuseppe Murdaca, Francesca Paladin, Gloria Mangini, Debora Tiso & Sebastiano Gangemi
Pages: 303-311
Published online: 23 Apr 2023
AbstractforTBC and COVID: an interplay between two infections | Full Text | References | PDF (494.3 KB) | EPUB
  • 121 Views
  • 0 CrossRef citations
  • 0Altmetric

Systematic Review and Meta-analysis

Article
Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis
Yakup Ergun, Gokhan Ucar & Baran Akagündüz
Pages: 313-322
Published online: 16 Apr 2023
AbstractforEfficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis | Full Text | References | PDF (3 MB) | EPUB
  • 173 Views
  • 0 CrossRef citations
  • 0Altmetric

Meta-analysis

Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, Antonio Cusmai, Mariarita Laforgia, Concetta Calabrò, Valentina Ungaro, Donato Oreste, Mario Sollitto, Gennaro Palmiotti & Giovanni Brandi
Pages: 323-329
Published online: 29 Nov 2022
AbstractforTreatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis | Full Text | References | PDF (2.6 MB) | EPUB
  • 256 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database
Yunfei Zhao, Huiling Wang, Qingsong Zhang, Yongxin Hu, Yulong Xu & Wei Liu
Pages: 331-338
Published online: 06 Oct 2022
AbstractforEvaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database | Full Text | References | PDF (2.2 MB) | EPUB
  • 272 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang & Guanghui Chen
Pages: 339-342
Published online: 05 Oct 2022
AbstractforA pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab | Full Text | References | PDF (188.4 KB) | EPUB | Supplemental
  • 485 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
Matilde Otero-Losada, Nikolai Petrovsky, Abdallah Alami, James A. Crispo, Donald Mattison, Francisco Capani, Christopher Goetz, Daniel Krewski & Santiago Perez-Lloret
Pages: 343-349
Published online: 07 Sep 2022
AbstractforDisproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom | Full Text | References | PDF (342.8 KB) | EPUB | Supplemental
  • 256 Views
  • 1 CrossRef citations
  • 0Altmetric

Explore articles